NASDAQ: ABVXAbivax Sa Stock
$15.78+0.04 (+0.25%)
Updated Apr 26, 2024
ABVX Price
$15.78
Fair Value Price
-$2.33
Market Cap
$993.02M
52 Week Low
$7.99
52 Week High
$17.02
P/E
-4.23x
P/B
4.66x
P/S
89.75x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.02M
Earnings
-$164.16M
Gross Margin
100%
Operating Margin
-2,593.92%
Profit Margin
-3,197.1%
Debt to Equity
0.67
Operating Cash Flow
-$108M
Beta
0.46
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ABVX Overview
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ABVX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABVX ($15.78) is overvalued by 776.63% relative to our estimate of its Fair Value price of -$2.33 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ABVX ($15.78) is not significantly undervalued (776.63%) relative to our estimate of its Fair Value price of -$2.33 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ABVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ABVX due diligence checks available for Premium users.
Be the first to know about important ABVX news, forecast changes, insider trades & much more!
ABVX News
Valuation
ABVX fair value
Fair Value of ABVX stock based on Discounted Cash Flow (DCF)
Price
$15.78
Fair Value
-$2.33
Undervalued by
776.63%
ABVX ($15.78) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ABVX ($15.78) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ABVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ABVX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.23x
Industry
14.88x
Market
41.14x
ABVX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.66x
Industry
5.85x
ABVX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABVX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
ABVX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ABVX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$363.4M
Liabilities
$145.6M
Debt to equity
0.67
ABVX's short-term assets ($310.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABVX's short-term assets ($310.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABVX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
ABVX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ABVX vs Biotech Stocks
Abivax Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.